Member Info for Adastra

P140 Lupuzor is entering a fully funded Ph3 dose escalation for lupus with known safety profile. Avion have committed £25m already so lots of their skin in the game.

P140 for CIPD also sitting in background.

BioAMBfor systemic fungal infections

BioCIN for severe bacterial infections

Both are in fields where we are running out of drugs active against these virulent infections.

And

Orano signed a 12 month cash up front deal in March last year....renewal...or...Any potential new cancer therapeutic using ImmuPharma’s peptide technology, discovered as part of the collaboration will be subject to a full licensing agreement between ImmuPharma and Orano in preparation for further development by Orano..

Ask yourself........surely this is work more than £6m...crazy.

But for the fact there are no similar treatments, that's why Lupuzor is different.

But this is not a one-trick pony - it has four other significant peptide assets. Far too lowly valued for a company of this stature and potential.

At this late stage in the development of Lupuzor alone it should be in the mid tens of millions MCap.

At last I'm not one of the only ones highlighting the huge discount to value here - great to see realization in action.

I just don't see the need for a discounted fundraise at this late stage with several triggers imminent. As for ramping the share read my posts. Cash is tight as I've highlighted and elucidated but also is access to bridging finance if needed from multiple potential sources (Avion Alora Monroe Orano). Lupuzor is now so far down the track as a Lupus treatment that Avion (parent Alora) is committed to seeing the Ph3 dose escalation through. This trial is increasing dosages by upto 15x previous trial given the excellent safety profile. These dosages should quickly identify the range giving clinically effective response. For a sub £10m MCap, even without its other drug candidates, at this stage of development it is criminally too cheap imo.

Couldn't resist more at that price myself.

Time will tell....

In all honesty mate if you loaded up yesterday or today at around 1.60 you'll be laughing.....spot on imo! Hat off to you.

100k @ 1.60 is a steal at this time imo.

I think now is the golden opportunity at this pullback imo. Last chance???

Loaded up??

Why do I think you landed up yesterday???? Welcome on board.

The multiple potential triggers for share appreciation here are that close you may well miss out. You are playing a risky strategy assuming that

a) further finance will be required before an RNS causes the share price to rise and negate it.

b) should any bridging finance be required Avion/Alora/Monroe or Orano would not provide it.

Jury's out, but end Feb by your own calculations is time enough for things to fall into place. Tight, but BoD will not want dilution of their own holdings.

Learned that gut-feeling on AIM makes me more cahones than pure logic at times.....not for widows and orphans but I see multi here at some point Q1.

Nope....knew the auto trading was going through at 1.60 but didn't know the platform. Thanks for the info just presumed this was dealer accumulation on behalf of ?

It's the off-market one that will surprise if/when it comes.

Incanthera is on Aquis not Immupharma.

It's in Ph3 and an indication of the commitment, time and cash that Avion have tied up in Lupuzor. You're also discounting any progression on the 12 month research collaboration with Frech giant Orano signed zmarch last year....quote...

For Orano, it is a real opportunity to evaluate the potential of a highly promising compound, combining one of our new radioisotopes with a promising peptide previously developed by Immupharma. This will enable us to expand and strengthen our pipeline of innovative radiopharmaceuticals." Plenty of triggers.

Rather than being dismissive it is worthwhile re-reading part of the joint collaboration agreement with Avion below:

Art Deas, Chief Executive Officer, Avion Pharmaceuticals added: “Avion is extremely pleased to sign

this partnership with ImmuPharma. After in-depth due-diligence around Lupuzor™, its mechanism of

action and learnings within the initial Phase III results, we believe that Lupuzor™ has a unique position

within lupus that sets it apart from competition, and we are delighted to be extending our footprint

within this therapeutic area. With approximately 1.5 million patients in the US suffering from lupus,

there is a significant unmet need for a safe and effective drug for this debilitating disease that we

believe Lupuzor™ can meet. We look forward to forging a strong and successful relationship with

ImmuPharma going forward.”

Not imo a company that will watch progress stagnate at this late stage.